| 10/23/00 | Cepheid Reports Third Quarter Results|
SUNNYVALE, Calif., Oct. 23 /PRNewswire/ -- Cepheid (Nasdaq: CPHD),
developers of accelerated, integrated DNA testing systems, today announced
financial results for the quarter and nine months ended September 30, 2000.
Cepheid reported a net loss of $3.8 million, or $0.15 per share on a pro forma
basis for the third quarter of 2000, compared to a net loss of $2.1 million,
or $0.19 per share on a pro forma basis for the third quarter of 1999. For
the nine months ended September 30,... |
| | 07/25/00 | Cepheid Reports Second Quarter Results|
SUNNYVALE, Calif., July 25 /PRNewswire/ -- Cepheid (Nasdaq: CPHD),
developers of accelerated, integrated DNA testing systems, today announced
financial results for the quarter and six months ended June 30, 2000. Cepheid
reported a net loss of $4.6 million, or $0.24 per share on a pro forma basis
for the second quarter of 2000, compared to a net loss of $2.1 million, or
$0.20 per share on a pro forma basis for the second quarter of 1999. For the
six months ended June 30, 2000, Cep... |
| | 06/21/00 | Cepheid Announces Initial Public Offering of Common Stock|
SUNNYVALE, Calif., June 21 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today
announced its initial public offering of 5,000,000 shares of common stock at
an initial public offering price of $ 6.00 per share. The initial offering
price represents a reduction from the proposed range of $10.00-$12.00 per
share. All of the shares are being offered by Cepheid. The shares commenced
trading today on the NASDAQ National Market under the symbol "CPHD."
UBS Warburg LLC was lead manager... |
| | 03/22/00 | Hollings Renton Named To Cepheid Board Of Directors| Sunnyvale, CA-- Cepheid today announced that Hollings C. Renton, president and chief executive officer of Onyx Pharmaceuticals, Inc. in Richmond, CA, has been elected to its board of directors. Before joining Onyx in 1993, Renton was president at Chiron Corporation. He joined Chiron in 1991 as president following the merger of Chiron and Cetus Corporation. He was president of Cetus since 1990 and executive vice president and chief operating officer since 1987 and chief financial officer since 19... |
| | 03/13/00 | Cepheid Elects Dr. Ernest Mario to Board of Directors| Sunnyvale, CA, March 14, 2000 … Cepheid today announced that Ernest Mario, Ph.D. has been elected to its board of directors. Dr. Mario is the chairman and chief executive officer of ALZA.
Prior to joining ALZA, Mario served as chief executive officer of Glaxo Holdings plc, a pharmaceutical corporation, from 1989 to March 1993. He also served as chairman and chief executive officer of Glaxo, Inc., a subsidiary of Glaxo Holdings, from 1988 to 1989 and as president and chief operating officer o... |
| | 02/01/00 | Cathy Smith Named Cepheid Chief Financial Officer| Sunnyvale, CA - Cepheid announced today that the company’s Board of Directors has named Cathy Smith to the newly created position of Chief Financial Officer. Ms. Smith had previously held the position of Vice President, Finance.
Ms. Smith, who began her career at the international public accounting firm Deloitte & Touche, has more than 14 years of financial experience in the life science industry. Prior to joining Cepheid, she was a financial management consultant to numerous biotechnology, p... |
|
|
Receive E-mail Alerts | 
RSS Feeds